Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rolls-Royce ups profit, cash flow guidance as H1 earnings surge

(Sharecast News) - Aerospace and defence engineer Rolls-Royce has raised its full-year guidance after a strong first half, in which underlying revenues grew by double-digits and operating profits surged by 50%. The company now expects to book an full-year underlying operating profit of £3.1bn-3.2bn for 2025, up from previous guidance of £2.7bn-2.9bn, while the free cash flow target has been upped to £3.0bn-3.1bn from £2.7bn-2.9bn.

Underlying revenues in the first half to 30 June totalled £9.06bn, up 13% over last year, helped by a 17% surge in Civil Aerospace sales to £4.79bn and a 20% jump in Power Systems to £2.04bn.

The Defence division registered just 1% growth in underlying revenues to £2.22bn, as 29% growth in Transport sales were offset by lower submarine revenues, which fell 19% due to a one-off gain the previous year.

Group underlying operating profit jumped to £1.73bn, up from £1.15bn a year earlier, as the operating margin jumped to 19.1% from 14.0%.

Free cash flow improved to £1.58bn from £1.16bn, driven by strong operating profit and continued long-term service agreement balance growth, the group said.

"Our multi-year transformation continues to deliver. Our actions led to strong first half year results, despite the challenges of the supply chain and tariffs. We are continuing to expand the earnings and cash potential of Rolls-Royce," said chief executive Tufan Erginbilgic.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.